The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, PKI is now linked to several cancers.”
From Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Research works printed but not linked: 36
- Burgering BM, Kops GJ . (2002). Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27: 352–360. · DOI · Paper page
- Chio CC, Chang YH, Hsu YW, Chi KH, Lin WW . (2004). PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. Cell Signal 16: 565–575. · DOI
- Cox ME, Deeble PD, Bissonette EA, Parsons SJ . (2000). Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendcrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 275: 13812–13818. · doi:10.1074/jbc.275.18.13812
- Dalton GD, Dewey WL . (2006). Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides 40: 23–34. · DOI · Paper page
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241. · DOI · Paper page
- Deeble PD, Cox ME, Frieson Jr HF, Sikes RA, Palmer JB, Davidson RJ et al. (2007). Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67: 3663–3672. · DOI
- Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM . (1998). Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743–1748. · DOI · Paper page
- Filippa N, Sable C, Filloux C, Hemmings B, Van Obberghen E . (1999). Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 19: 4989–5000. · DOI · Paper page
- Gamm DM, Uhler MD . (1995). Isoform–specific differences in the potencies of murine protein kinase inhibitors are due to unconserved amino-terminal residues. J Biol Chem 270: 7227–7232. · doi:10.1074/jbc.270.13.7227
- Gronberg H . (2003). Prostate cancer epidemiology. Lancet 361: 859–864. · DOI · Paper page
- Grossmann ME, Huang H, Tindall DJ . (2001). Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 93: 1687–1697. · DOI · Paper page
- Hay N . (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179–183. · DOI · Paper page
- Hsing AW, Devesa SS . (2001). Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3–13. · DOI · Paper page
- Knighton DR, Zheng JH, Teneyck LF, Xuong NH, Taylor SS, Sowadski JM . (1991). Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253: 414–420. · DOI · Paper page
- Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. (2004). Phosphorylation of Akt(Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232–5236. · DOI · Paper page
- Lalli E, Sassone-Corsi P . (1994). Signal transduction and gene regulation: the nuclear response to cAMP. J Biol Chem 269: 17359–17362. · DOI · Paper page
- Majumder PK, Sellers WR . (2005). Akt-regulated pathways in prostate cancer. Oncogene 24: 7465–7474. · DOI · Paper page
- Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al. (2002). Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168–1171.
- McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V et al. (2008). Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68: 1618–1624. · DOI · Paper page
- Miller WR . (2002). Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci 968: 37–48. · doi:10.1111/j.1749-6632.2002.tb04325.x
- Mitsiades CS, Mitsiades N, Koutsilieris M . (2004). The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4: 235–256. · DOI · Paper page
- Orloff MS, Eng C . (2008). Genetic and phenotypic heterogeneity in the PTEN hamartoma tumor syndrome. Oncogene 27: 5387–5397. · DOI
- Pap M, Cooper GM . (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273: 19929–19932. · DOI · Paper page
- Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. (2004). Docetaxel and estramustine compared with mitoxantrone and predonisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520. · DOI · Paper page
- Sadar MD . (1999). Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274: 7777–7783. · DOI · Paper page
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . (2005). Phosphorylation and regulation of Akt/PKB by Rictor-mTOR complex. Science 307: 1098–1101. · DOI · Paper page
- Scheid MP, Woodgett JR . (2001). PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2: 760–768. · DOI · Paper page
- Shaywitz AJ, Greenberg ME . (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821–861. · DOI · Paper page
- Stork PJ, Schmitt JM . (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258–266. · DOI · Paper page
- Tamura K, Furihata M, Tsunoda T, Ashida A, Takata R, Obara W et al. (2007). Molecular features of hormone-refractory prostate cancer cells by genome-wide gene-expression profiles. Cancer Res 67: 5117–5125. · DOI · Paper page
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. (2004). Docetaxel plus predonisone or mitoxantrone plus predonisone for advanced prostate cancer. N Engl J Med 351: 1502–1512. · DOI · Paper page
- Tasken K, Aandahl EM . (2004). Localized effects of cAMP mediated by distinct routes of protein kinase A. Physol Rev 84: 137–167.
- Taylor SS, Kim C, Vigil D, Haste NM, Yang J, Wu J et al. (2005). Dynamics of signaling by PKA. Biochim Biophys Acta 1754: 25–37. · DOI · Paper page
- Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2: 289–301. · DOI · Paper page
- Wen W, Harootunian AT, Admas SR, Feramisco J, Tsien RY, Meinkoth JL et al. (1994). Heat-stable inhibitors of cAMP-dependent protein kinase carry a nuclear export signal. J Biol Chem 269: 32214–32220. · DOI
- Wiley JC, Wailes LA, Idzerda RL, McKnight GS . (1999). Role of regulatory subunits and protein kinase inhibitor (PKI) in determining nuclear localization and activity of the catalytic subunit of protein kinase A. J Biol Chem 274: 6381–6387. · doi:10.1074/jbc.274.10.6381
Cited by
Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A
Taylor, S. S., Herberg, F. W., Veglia, G., & Wu, J. (2023) · IUBMB Life · doi:10.1002/iub.2714 · Cited by 15
Metadata
- Authors
- Chung, S., Furihata, M., Tamura, K., Uemura, M., Daigo, Y., Nasu, Y., Miki, T., Shuin, T., Fujioka, T., Nakamura, Y., & Nakagawa, H.
- Venue
- Oncogene
- Published
- 2009-06-01
- Volume
- 28
- Issue
- 32
- Pages
- 2849-2859
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 33
- References
- 2
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.